Zacks Research Analysts Raise Earnings Estimates for TEVA

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Equities research analysts at Zacks Research upped their Q1 2025 earnings estimates for Teva Pharmaceutical Industries in a report released on Wednesday, November 27th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.48 for the quarter, up from their previous estimate of $0.46. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.34 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q2 2025 earnings at $0.59 EPS, Q1 2026 earnings at $0.48 EPS and Q3 2026 earnings at $0.82 EPS.

Several other equities analysts have also weighed in on TEVA. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $19.67.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.14 during trading hours on Monday, hitting $16.64. 2,765,191 shares of the stock traded hands, compared to its average volume of 9,189,887. Teva Pharmaceutical Industries has a one year low of $9.35 and a one year high of $19.31. The company has a market cap of $18.85 billion, a P/E ratio of -19.74, a P/E/G ratio of 1.30 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The stock has a 50-day simple moving average of $17.56 and a 200 day simple moving average of $17.35.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Franklin Resources Inc. lifted its position in shares of Teva Pharmaceutical Industries by 141.7% during the third quarter. Franklin Resources Inc. now owns 155,091 shares of the company's stock worth $2,674,000 after purchasing an additional 90,920 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $50,000. Sanctuary Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after purchasing an additional 664 shares during the period. TCW Group Inc. acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $1,286,000. Finally, Geode Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 3.4% in the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company's stock valued at $157,571,000 after purchasing an additional 291,124 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.